High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.
Don't miss the next one like this
New education grants in US open all the time. Get a free weekly email with only the ones that match — nothing else.
Want help winning this?
Enter your email and we'll send the official application link, deadlines and pointers right away — free. Want a hand? Tick the box and we'll introduce you to a vetted grant or bid writer. The intro's free, and you only pay if you choose to work with them.
- Eligibility
- Open to nonprofit organizations. Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Related opportunities
See all alternatives →Recruitment of Education and Research Specialist to support the Learning and Evidence Agenda for Regional Collaboration in Eastern and Southern Africa (LEARN-ESA) (P516274)
→Recruitment of Education and Research Specialist to support the Learning and Evidence Agenda for Regional Collaboration in Eastern and Southern Africa (LEARN-ESA) (P516274)
TenderCloses in 8 daysEducationSELECTION OF CONSULTANT FIRMS FOR POST-CONTRACT SERVICES FOR THE CONSTRUCTION OF NEW SCHOOLS, UPGRADE AND REHABILITATION OF EXISTING SCHOOLS
→SELECTION OF CONSULTANT FIRMS FOR POST-CONTRACT SERVICES FOR THE CONSTRUCTION OF NEW SCHOOLS, UPGRADE AND REHABILITATION OF EXISTING SCHOOLS
TenderCloses in 10 daysEducationThe Selection of Technical and Vocational Education and Training (TVET) Senior Coordinator
→The Selection of Technical and Vocational Education and Training (TVET) Senior Coordinator
TenderCloses in 9 daysEducationThe selection of Digital Transformation Senior Coordinator
→The selection of Digital Transformation Senior Coordinator
TenderCloses in 9 daysEducationRehabilitation of Shelters (Public Schools) Batch 5: Lot 1 (Jezzine and Chouf), Lot 2 (West Bekaa, Zahle and Rashaya) and Lot 3 (Saida and Hasbaya)
→Rehabilitation of Shelters (Public Schools) Batch 5: Lot 1 (Jezzine and Chouf), Lot 2 (West Bekaa, Zahle and Rashaya) and Lot 3 (Saida and Hasbaya)
TenderCloses in 5 daysEducationNIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
→This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research training and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research.
Grant$750KCloses 2026-11-13USEducation
People also viewed
Other grants visitors looked at from National Institutes of Health.
Maximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)
→This NOFO seeks to advance research and training in high-priority areas of child health by stimulating the use of Environmental Influences on Child Health Outcomes (ECHO) Cohort data by postdoctoral fellows from relevant scientific disciplines. This RFA will provide opportunities for fellows to study child health outcomes through the analysis of ECHO's large longitudinal data sets within the NICHD Data and Specimen Hub (DASH) repository. ECHO's DASH dataset integrates de-identified longitudinal data from more than 71,000 participants across the U.S. Prenatal and child exposure data include physical, chemical, social, behavioral, and biological factors. ECHO's five primary pediatric outcome areas are pre-, peri-, and postnatal outcomes, upper and lower airway, obesity, neurodevelopment, and positive health.
GrantCloses 2026-12-02USHealthNIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed)
→The purpose of this notice of funding opportunity (NOFO) is to provide salary support for exceptional Research Software Engineers (RSEs) that contribute their skills to the development and dissemination of biomedical, behavioral or health related software, tools, and algorithms as well as to the training of prospective users of these tools.
GrantCloses 2026-12-04USEducationPrevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
→This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and that (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider NOFO (TEMP-23832, the R34 option).
GrantCloses 2026-11-17USHealthSeamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
→The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.
GrantCloses 2026-11-19USHealth
Always confirm details on the official source before applying — see our methodology.